Diagnostic value of additional 68Ga-PSMA-PET before 223ra-dichloride therapy in patients with metastatic prostate carcinoma

NuklearMedizin

Volumn 56, Issue 1, 2017, Pages 14-22

  Bräuer, Axel ^a   Rahbar, Kambiz ^a   Konnert, Julia ^a   Bögemann, Martin ^a   Stegger, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

223Ra dichloride; 68Ga PSMA PET; Bone metastases; Bone scintigraphy; Prostate cancer; Xofigo

Indexed keywords

DOCETAXEL; MEDRONIC ACID; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIUM CHLORIDE RA 223; EDETIC ACID; GLU-NH-CO-NH-LYS-(AHX)-((68)GA(HBED-CC)); OLIGOPEPTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; RETINA IMAGE; VISCERAL METASTASIS; AGED; ANALOGS AND DERIVATIVES; CARCINOMA; DIAGNOSTIC IMAGING; MALE; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; REPRODUCIBILITY; RETROSPECTIVE STUDY; SECONDARY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA; EDETIC ACID; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85012878964     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0846-16-09     Document Type: Article

References (24)

1. Afshar-Oromieh A, Babich JW, Kratochwil C et al. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. J Nucl Med 2016; 57: 79S-89S.
2. 68Ga)Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39: 1085–1086.
3. 68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept. J Nucl Med 2016; DOI: jnumed.116.178533 (Epub ahead of print).
4. Ahmadzadehfar H, Essler M, Schäfers M, Rahbar K. Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use. Nucl Med Biol 2016; 43(12): 835.
5. Bier G, Hoffmann V, Kloth C et al. CT imaging of bone and bone marrow infiltration in malignant melanoma-Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. Eur J Radiol 2016; 85: 732–738.
6. Bode A, Rahbar K, Konnert J et al. Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy. Clin Nucl Med 2016; 41(12): 951–952.
7. 99Tcm-MDP. Br J Radiol 1989; 62: 318–320.
8. 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668–674.
9. 177Lu-PSMA-617 therapy, dosimetry and fol-low-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin 2016; 55(3): 123–128.
10. Giovanella L, Castellani M, Suriano S et al. Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. Tumori 2011; 97: 629–633.
11. Hawkins T, Halewood MM. Technical note: identifying the prostate cancer ‚superscan‘ by quantitative skeletal scintigraphy. Nucl Med Commun 2008; 29: 654–659.
12. itG. Ga-68 Radiolabeling KIT, Operating Manual, Version 1.0, Status 01/2014, itG, Garching, Germany, 2014.
13. 99Tcm-DPD in pathologic bone lesions. A visual and quantitative comparison. Acta Radiol 1987; 28: 631–633.
14. O‘Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol 2015; 7: 202–211.
15. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 2013; 369(3): 213–223.
16. Pfister D, Porres D, Heidenreich A et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-Fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging 2016; 43: 1410–1417.
17. 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2016; DOI: jnumed.116.183194 (Epub ahead of print).
18. 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med 2016; 41: 522–528.
19. 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. J Nucl Med 2016; 57(9): 1334–1338.
20. 68Ga-PSMA Distribution in Patients with Prostate Cancer. J Nucl Med 2016; 57: 563–567.
21. 18F-Flu-oride PET/CT. J Nucl Med 2015; 56: 1507–1512.
22. Sartor O, Coleman R, Nilsson S et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014; 15: 738–746.
23. Torre LA, Bray F, Siegel RL et al. Global cancer statistics 2012. CA Cancer J Clin 2015; 65: 87–108.
24. Wakabayashi H, Nakajima K, Mizokami A et al. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med 2013; 27: 802–807.